| |
|
| |
 |
GENETICALLY INFORMED MEDICINE |
|
| |
Coimbra Genomics develops tools that bring genomic
knowledge to the desktop of every doctor, making personalized
medicine a reality. Because health is a personal matter. |
Coimbra Genomics develops tools that give medical doctors easy access to the ever growing wealth of genomic information, and help them apply it for the benefit of their patients, in useful time and in a practical manner. Aiming to stay at the forefront of genomic knowledge, Coimbra Genomics also leads innovative R&D projects in search for biomarkers for important unmet medical needs.
Coimbra Genomics was launched by Critical Software, the Biocant Park and a group of experienced entrepreneurs and scientists. The company was funded by two VC firms and is partnering with a growing network of physicians, from several specialties, in leading healthcare units.
|
|
|
PRODUCTS & SERVICES
Coimbra Genomics develops software tools for precision medicine. Our technology allows any Medical Doctor, anywhere, to consult their patients’ genome or exome sequence through standardized queries, and quickly obtain easy-to-read reports with validated information relevant for the clinical decisions at stake. We provide a simple, scalable and secure way to perform personalized medicine.
Coimbra Genomics’ technology can be used by any physician, regardless of previous knowledge in genetics, without stopping patient flow or requiring learning on the spot. Its extreme flexibility allows coupling to any sequencing technology (Illumina, LifeTech, Complete Genomics, etc) and compliance with different legal and logistic requirements. One of the system’s several additional features permits the accumulation of clinical data and its matching to genetic information to unveil valuable genome-phenome correlations.
Aiming to stay at the forefront of genomic knowledge, Coimbra Genomics also leads innovative R&D projects in search for biomarkers of diseases representing important unmet medical needs. The first such project focuses on gastric cancer and has begun in late 2013 with the genomic, transcriptomic and methylomic characterization of 100 well-characterized samples in collaboration with BGI and expert cancer center IPATIMUP.
|
|
TARGET MARKETS / CLIENTS
Medical doctors of all specialties; healthcare centers.
Europe, North America, Latin America, Asia.
|
|
|
